Trial Profile
A multicentre, randomized, open-label, single dose, two-treatment, three-period, three sequence, partial replicate, crossover, pivotal bioequivalence study of Test capecitabine 500 mg tablets manufactured by Reliance Life Sciences Pvt. Ltd., India with Xeloda (capecitabine 500 mg) manufactured by Roche Pharma AG, Germany in adult, human, cancer patients under fed condition
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Advanced breast cancer; Colorectal cancer
- Focus Pharmacokinetics
- Sponsors Reliance Life Sciences
- 24 Jan 2012 New trial record